Syringomycin E @R-E) is a low molecular weight bacterial lipodepsipeptide with antifungal properties. Owing to immunosuppressive activities of such compounds as cyclosporine, FK506 and rapamycin, we studied the effect of SR-E on proliferation of human blood lymphocytes in vitro. SR-E, by itself, had no effect but the mitogen-induced lymphocyte proliferation was significantly suppressed. The suppressive effect was more pronounced with pokeweed mitogen (PWM) as compared to phytohemagglutinin (PHA) or monoclonal antibody to CD3 (anti-CD3). Since these mitogens induce cellular immunity (T cell-dependent), SR-E may potentially be a novel immunosuppressive compound.
Introduction
The syringomycins are biomembrane-active cyclic lipodepsipeptides produced by certain strains of the plant bacterium Pseua!omonm syringae pv. syringae [ 1, 2] . The most abundant and active form is syringomycin E @R-E) with .a molecular weight of 1224. It is composed of a hydroxydodecanoic acyl chain linked to a cyclic nonapeptide with rare amino acids such as chlorothreonine, P-hydroxyaspartic acid and 2,4-diaminobutyric aci.d [3] . Long considered a phytotoxin [4, 5] , SR-E is a potent antifungal agent particularly against yeast [2] . Because several other naturally occurring antifungal substances (cyclosporine A, FK506, and r,apamycin) and their synthetic analogs manifest immunosuppressive activities [6], we investigated the immune effect of SR-E. We report that SR-E at low concentrations suppressed mitogen-induced lymphocyte proliferation.
Materials and methods
Peripheral blood mononuclear cells (MNC) (containing lymphocytes and monocytes) were separated by Ficoll-Hypaque density-gradient centrifugation as outlined previously [7] . However, it should be mentioned that the MNC used here were the cells left over from Dr. Singh's other research projects which were approved by the Institutional Review Board (IRB) Committee. Informed consent was obtained from all blood donors. All subjects were normal adults between 21 to 40 years of age.
Mitogen-induced lymphocyte proliferation was determined as described previously [7] . Briefly, MNC were cultured in triplicate in 96-well microtiter plates (Coming, Inc.). The cultures (final volume of 200 ~1) contained 10 X lo5 cells, various mitogens and different concentrations of SR-E in RPMI-1640 containing fetal bovine serum at a final concentration of 5% (V/V). Blank cultures did not contain any mitogen or SR-E. They were incubated for 4 days in a humified chamber with 5% CO, at 37°C. They were pulsed for 4 h with 0.5 pCi/well of [3H]metbylthymidine (spec. act. = 25 Ci/mmol from Amersham Intl.). The cultures were harvested using a semi-automatic cell harvester (Skatron Instruments) onto glass fiber filter paper discs, air-dried and transferred to vials. To each vial, 2 ml of CytoScint fluid (ICN Biomedicals) was dispensed. The radioactivity was determined using a liquid scintillation counter (Model Tri-Carb, Packard). The rate of [3H]thymidine by MNC was calculated as counts per min (cpm) per 10' cells. Lymphocyte proliferation was performed with three mitogens: PHA, PWM, and anti-CD3. PHA and PWM (Sigma Chemical Co.) and anti-CD3 @MAC, Inc) were used at final concentrations of 10 )*g, 20 p,g and 0.4 p,g per ml, respectively.
SR-E was purified as described previously [8] . A stock solution (10 mg/ml) was prepared in RPMI-1640, sterile filtered (0.4 p,m size Millipore filter) and stored at -20°C. It was thawed on ice, diluted appropriately and used fresh in lymphocyte cultures.
Results and discussion
We investigated the effect of SR-E on human blood lymphocytes in vitro measuring their proliferative response [7] . As expected, each of the three mitogens (PHA, PWM and anti-CD3) stimulated lymphocyte proliferation several fold above the baseline control (no mitogen). SR-E at concentrations of 5.72 pM and lower had no effect in the absence of mitogens (Fig. 1) . However, the mitogen-induced proliferation of lymphocytes was suppressed by SR-E (Fig. 2) . The extent of inhibition by SR-E varied depending upon the mitogen used. The PWM response was inhibited to a greater degree than the PHA and anti-CD3 responses, i.e. with 5.72 pM SR-E, 60% inhibition of PWM response (P = 0.0 17) 25% inhibition of PHA response (P = 0.026) and 30% inhibition of anti-CD3 response (P = 0.02).
Moreover, SR-E at a five times lower concentration (i.e. 1.14 FM) significantly (P = 0.004) inhibited PWM response but not the other two responses. The maximum lymphocyte proliferation (100% response) was 59 770 f 8602 cpm (PHA), 20901 f 2072 cpm (PWM) and 9927 i-2809 cpm (anti-CD3). All other details were the same as described in Section 2, Mateials and methods. The data represent the mean of three experiments (4 blood donors) each with triplicate assays.
Lymphocyte stimulation with mitogens is a measure of cell-mediated immunity, and it can be used to assess the subset of lymphocytes affected [9] . Inhibition of PHA-and anti-CD3-induced lymphocyte proliferation by SR-E suggested that it suppressed cellular immunity (T cell function). Both PHA and anti-CD3 are well known activators of T lymphocytes although they act through different mechanisms. The anti-CD3 activates T cells via the T cell antigen receptor (TcR/CD3 complex) [lo] whereas PHA induces the interleukin-2 (IL-2)/IL-2 receptor (IL-2R) complex [ll] . In addition, the suppression of PWM-induced proliferation would imply that SR-E also influences humoral immunity since PWM is a polyclonal activator of T cell-dependent antibody production by B cells.
Microbial products ,such as cyclosporine A (CsA), FK506 and rapamycin are well known immunosuppressive compounds [6] . Their immunosuppressive properties result mainly from a selective suppression of T lymphocyte function. They act at different targets of T cell activation, for instance CsA interacts with TcR/CD3 complex whereas rapamycin and FK506 interact with IL-2/IL-2R complex. Recently, tepoxalin, a synthetic immunosuppressive agent, was shown to act through a T cell mechanism that was most resistant to CsA [12] . However, tepoxalin was synergistic with CsA in suppressing anti-CD3-induced T cell proliferation, suggesting that this colmpound can inhibit CsA-interactive pathway also. In our present study, we found that SR-E suppressed both T cell (PHA and anti-CD31 and T cell-dependent B cell (PWM) responses, the latter being more pronounced. Based on this observation, we suggest that SIR-E may be a novel naturally occurring immunosuppressive agent.
